Biogen QALSODY — Total Revenue increased by 30.0% to $32.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 109.7%, from $15.50M to $32.50M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful market penetration and growing demand for the therapy, while a decrease may signal competitive pressure or loss of market share.
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeut...
Comparable to product-specific revenue lines reported by other biopharmaceutical companies for their key commercialized assets.
biib_segment_qalsody_total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $900.00K | $1.70M | $3.30M | $4.60M | $5.00M | $11.10M | $11.70M | $15.50M | $20.00M | $26.40M | $25.00M | $32.50M |
| QoQ Change | — | — | — | — | — | — | — | — | — | +88.9% | +94.1% | +39.4% | +8.7% | +122.0% | +5.4% | +32.5% | +29.0% | +32.0% | -5.3% | +30.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | +455.6% | +552.9% | +254.5% | +237.0% | +300.0% | +137.8% | +113.7% | +109.7% |